EZH2/BCL2 coexpression was independently associated with worse EFS in DLBCL-NOS (HR 3.43, p = 0.026), even after adjustment for BCL2-positivity and double-expressor status. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.